First author: S Alehashemi
Journal : Arthritis and Rheumatology
Reference : DOI : 10.1002/art.42664
Link to article: https://pubmed.ncbi.nlm.nih.gov/37488949/
Injection site reactions are common in patients receiving Anakinra. Patients often experience a burning sensation with erythema; this adverse effect disappears with rotation of injection sites. The authors of this article previously described the development of Anakinra-associated amyloidomas as a late complication of Anakinra injections in two patients with Cryopyrin-Associated Periodic Syndromes (CAPS). This form of amyloidosis (AIL1RAP [IL-1 receptor antagonist protein (IL-1Ra)]) is now recognized as a type of amyloidosis by the Nomenclature Committee of the International Amyloidosis Society The authors report here the first case of iatrogenic systemic amyloidosis, occurring as AIL1RAP amyloidosis in a CAPS patient treated with Anakinra.
Comments